Kissei Pharmaceutical Co., Ltd.
Notice on the Status of Treasury Stock Acquisition (Treasury Stock Acquisition Based on the Provisions of Article 165, Paragraph 2 of the Companies Act)
The target for acquisition is our common stock, with cumulative results of 0 shares and 0 yen. The upper limit is 1,300,000 shares (3.14% of issued shares) and upper limit of 6,000,000,000 yen, with periods from 2026/5/12 to 2026/12/31. As of July 31, 2026, the cumulative total is 0 shares and 0 yen.
Key Figures
- Total number of treasury stock acquired: 0 shares (cumulative)
- Total acquisition value: 0 yen (cumulative)
- Upper limit number of shares: 1,300,000 shares (3.14% of issued shares)
AI要約
Overview
This notice provides the progress of the treasury stock acquisition project based on the board of directors meeting resolution held on May 11, 2026. The target shares are common stock, with an upper limit of 1,300,000 shares (3.14% of issued shares) and the upper total amount of 6,000,000,000 yen. The acquisition periods are from July 1, 2026 to July 31, 2026 (execution-based) and from May 12, 2026 to December 31, 2026, planned as market purchases across multiple periods; as of July 31, 2026, the cumulative total is 0 shares and 0 yen.
Outlook and Impact on Shareholders
This demonstrates the policy of treasury stock acquisition through market purchases. The current cumulative total of 0 shares provides information on the practical avoidance of dilution. Acquisition methods include market purchases via ToSTNeT-3 and entrusted trading agreements, and progress during the period may aim to stabilize shareholder value.
キーセイ薬品工業株式会社
Company overview · Stock price · Financial data · All IR
